Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Indian Journal of Hematology and Blood Transfusion
Literature
1.
Mishra K, Jandial A, Sandal R, Lad D, Prakash G, Khadwal A et al (2019) Poor mobilisation after daratumumab based combination chemotherapy in patients of newly diagnosed multiple myeloma. Indian J Hematol Blood Transfus 35:584–586CrossRef
2.
Ma X, Wong SW, Zhou P, Chaulagain CP, Doshi P, Klein AK et al (2018) Daratumumab binds to mobilised CD34+ cells of myeloma patients in vitro without cytotoxicity or impaired progenitor cell growth. Exp Hematol Oncol 7:27CrossRef
3.
Yimer H, Melear J, Faber E, Bensinger WI, Burke JM, Narang M et al (2019) Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study. Br J Haematol 185:492–502CrossRef
4.
Voorhees PM, Rodriguez C, Reeves B, Nathwani N, Costa LJ, Lutska Y et al (2018) Efficacy and updated safety analysis of a safety run-in cohort from griffin, a phase 2 randomized study of daratumumab (dara), bortezomib (V), lenalidomide (R), and dexamethasone (D; Dara‐Vrd) Vs. Vrd in patients (Pts) with newly diagnosed (ND) multiple myeloma (MM) eligible for high‐dose therapy (HDT) and autologous stem cell transplantation (ASCT). Blood 132(Supplement 1):151. https://​doi.​org/​10.​1182/​blood-2018-151CrossRef
5.
6.
Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L et al (2019) Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet 394:29–38CrossRef
7.
Stiff PJ, Micallef I, Nademanee AP, Stadtmauer EA, Maziarz RT, Bolwell BJ et al (2011) Transplanted CD34(+) cell dose is associated with long-term platelet count recovery following autologous peripheral blood stem cell transplant in patients with non-Hodgkin lymphoma or multiple myeloma. Biol Blood Marrow Transpl 17:1146–1153CrossRef
8.
9.
10.
Gavriatopoulou M, Kastritis E, Ntanasis-Stathopoulos I, Fotiou D, Roussou M, Migkou M et al (2018) The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents. Blood 131:464–467CrossRef
11.
Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Gastineau DA et al (2007) Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 21:2035–2042CrossRef
12.
13.
Xu XS, Dimopoulos MA, Sonneveld P et al (2018) Pharmacokinetics and exposure-response analyses of daratumumab in combination therapy regimens for patients with multiple myeloma. Adv Ther 35:1859–1872CrossRef
14.
Shaughnessy P, Islas-Ohlmayer M, Murphy J, Hougham M, MacPherson J, Winkler K et al (2011) Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide. Biol Blood Marrow Transpl 17:729–736CrossRef
15.
Carrancio S, Blanco B, Romo C, Muntion S, Lopez-Holgado N, Blanco JF et al (2011) Bone marrow mesenchymal stem cells for improving hematopoietic function: an in vitro and in vivo model. Part 2: effect on bone marrow microenvironment. PLoS ONE 6:e26241CrossRef
16.
Metadata
Title
Peri-transplant Stem Cell Kinetics After Daratumumab-Based Induction in Patients with Multiple Myeloma: Response to Mishra et al
Author
Ankur Jain
Publication date
01-10-2020
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion / Issue 4/2020
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-020-01273-0

Other articles of this Issue 4/2020

Indian Journal of Hematology and Blood Transfusion 4/2020 Go to the issue

Original Article

Demographical and Clinical Features of Marginal Zone Lymphomas: A Retrospective Study of Turkish Oncology Group (TOG)

Original Article

JAK2V617F Mutation in Patient with Splanchnic Vein Thrombosis

Images

AML-MRC with Basophilia Mimicking CLPD Due to Abnormally Clumped Chromatin

Correspondence

Consumables Quality: Is It Critical for Transfusion Services?

Original Article

The Efficacy of Cladribine (2-CdA) in Advanced Systemic Mastocytosis

Original Article

Post-transplant Hemophagocytic Lymphohistiocytosis in Benign Hematological Disorders: Experience of 4 Cases with Review of Literature
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits